Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2b observational study for prevention of HBV-related hepatocellular carcinoma in high-risk patients
ChiCTR2200066281Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Oct 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Liver imaging at 48 weeks, Hepatitis B virus index at 48 weeks and 2 more. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2200066281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066281.